Tirzepatide 30mg

Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, offering a novel approach for research into glycemic control and obesity management. By activating both incretin pathways, tirzepatide enhances insulin secretion, suppresses glucagon, and promotes significant weight loss through appetite suppression. Preclinical and clinical studies have demonstrated its superior efficacy in improving glycemic parameters and reducing body weight compared to traditional GLP-1 receptor agonists. Tirzepatide’s long half-life supports once-weekly dosing, enabling efficient longitudinal studies. It continues to be an important molecule in the exploration of next-generation therapeutics for metabolic diseases.

This product is intended solely for laboratory research use and is not approved for human or veterinary applications, diagnostic procedures, therapeutic uses, or consumption. All products are sold under the condition that they will be handled exclusively by qualified individuals familiar with their use and potential risks. Any application of this material in humans or animals for therapeutic or diagnostic purposes must comply with the regulations established in 21 CFR 312 and 21 CFR 600.